BACKGROUND: Capecitabine and docetaxel have demonstrated preclinical antitumor synergy and activity in advanced gastric cancer. We assessed the clinical activity and the toxicity of weekly docetaxel in combination with capecitabine in untreated patients with advanced gastric cancer. PATIENTS AND METHODS: A total of 38 patients were treated with docetaxel 36 mg/m2 on days 1, 8, and 15 i.v., plus capecitabine, 625 mg/m2 bid per os on days 5 to 18 repeated every 4 weeks. RESULTS: All patients were assessable for response to treatment and for toxicity. Major responses were observed in eight patients (21%), with three patients achieving a CR (7.8%) and five showing a PR (13%). The median time to progression was 5.4 months and the overall survival was 7.7 months. The safety profile of this schedule was acceptable with a low rate of myelossuppression, diarrhoea and hand-foot syndrome. CONCLUSIONS: The combination of docetaxel and capecitabine at the doses and schedule investigated in this study is safe, but does not show significant activity in untreated patients with advanced gastric cancer.
BACKGROUND:Capecitabine and docetaxel have demonstrated preclinical antitumor synergy and activity in advanced gastric cancer. We assessed the clinical activity and the toxicity of weekly docetaxel in combination with capecitabine in untreated patients with advanced gastric cancer. PATIENTS AND METHODS: A total of 38 patients were treated with docetaxel 36 mg/m2 on days 1, 8, and 15 i.v., plus capecitabine, 625 mg/m2 bid per os on days 5 to 18 repeated every 4 weeks. RESULTS: All patients were assessable for response to treatment and for toxicity. Major responses were observed in eight patients (21%), with three patients achieving a CR (7.8%) and five showing a PR (13%). The median time to progression was 5.4 months and the overall survival was 7.7 months. The safety profile of this schedule was acceptable with a low rate of myelossuppression, diarrhoea and hand-foot syndrome. CONCLUSIONS: The combination of docetaxel and capecitabine at the doses and schedule investigated in this study is safe, but does not show significant activity in untreated patients with advanced gastric cancer.
Authors: Thomas Makatsoris; Pavlos Papakostas; Haralabos P Kalofonos; Ioannis Xanthakis; Dimitrios Tsavdaridis; Gerasimos Aravantinos; Helen Gogas; George Klouvas; Paris Kosmidis; Dimitrios Pectasides; George Fountzilas Journal: Med Oncol Date: 2007 Impact factor: 3.064
Authors: P C Thuss-Patience; A Kretzschmar; Y Dogan; F Rothmann; I Blau; I Schwaner; K Breithaupt; D Bichev; M Grothoff; C Grieser; P Reichardt Journal: Br J Cancer Date: 2011-07-26 Impact factor: 7.640
Authors: C Pinto; F Di Fabio; C Barone; S Siena; A Falcone; S Cascinu; F L Rojas Llimpe; G Stella; G Schinzari; S Artale; V Mutri; S Giaquinta; L Giannetta; A Bardelli; A A Martoni Journal: Br J Cancer Date: 2009-09-22 Impact factor: 7.640
Authors: N C Tebbutt; M M Cummins; T Sourjina; A Strickland; G Van Hazel; V Ganju; D Gibbs; M Stockler; V Gebski; J Zalcberg Journal: Br J Cancer Date: 2010-01-12 Impact factor: 7.640
Authors: S R Park; H K Kim; C G Kim; I J Choi; J S Lee; J H Lee; K W Ryu; Y-W Kim; J-M Bae; N K Kim Journal: Br J Cancer Date: 2008-03-25 Impact factor: 7.640